Fig. 2: Vaccination after SARS-CoV-2 infection boosts spike-specific antibody titers independent of persisting sequelae.
a Schematic representation of vaccination and sampling of the DigiHero cohort. b Proportion of administered vaccines in individuals with single-dose vaccinations. c Migration plot indicating distribution of administered vaccines in individuals who received two post-infection vaccine doses before sampling. d, e Relative S1 and NCP-specific IgG antibody titers in post-infection PCC-related groups and uninfected individuals plotted as means with respect to vaccination status (d) or as Tukey’s box-plot with respect to vaccination status and sex (e). In e, the centre line represents the median, lower bounds of boxes indicate the first quartile, upper bound the third quartile. Whiskers indicate the 1.5 interquartile range (IQR), dots above or below whiskers indicate data points outside 1.5 IQR. Dotted lines indicate signal threshold for positivity. Group sizes: Individuals with ongoing PCC who were unvaccinated (n = 30, 25 females, 5 males), received one vaccination (n = 72, 50 females, 22 males) or two vaccinations (n = 37, 24 females, 13 males); Individuals who resolved PCC and were unvaccinated (n = 29, 19 females, 10 males), received one vaccination (n = 76, 48 females, 28 males) or two vaccinations (n = 26, 15 females, 11 males); Individuals who never reported PCC and were unvaccinated (n = 23, 11 females, 12 males), received one vaccination (n = 69; 32 females, 37 males) or two vaccinations (n = 34; 17 females, 17 males); Individuals without COVID-19 who were unvaccinated (n = 12), received one vaccination (n = 5) or two vaccinations (n = 56). Statistics: Group comparisons were performed using ordinary one-way ANOVA followed by post-hoc testing (Tukey’s multiple comparisons test). The calculated p values for ANOVA are indicated in (d), p values in (e) represent post hoc analyses for female vs mal comparisons. f Linear regression and Pearson correlation analysis for S1-IgG or NCP-IgG titers and sampling time point in months after first symptoms of COVID-19 for unvaccinated individuals with ongoing PCC (n = 29), who resolved PCC (n = 22) or who never reported PCC (n = 23). Correlation coefficient R2, Pearson correlation coefficients (rP) and p values are indicated.
